Answers are grounded in this paper and cite their sources.
tRNA-derived fragments (tRFs) have arisen as critical regulators in cancer development, however, their functions in esophageal squamous cell carcinoma (ESCC) remain poorly understood. Here, we reported that tRF-17-9L5FZU3 was significantly upregulated in ESCC cells and tissues, and correlated with poor patient outcome. Through integrated small RNA sequencing and qRT-PCR validation in 40 paired clinical samples, functional analyses, including colony formation, CCK-8, Transwell migration/invasion assays, and xenograft mouse models, demonstrated that tRF-17-9L5FZU3-knockdown suppresses ESCC cell proliferation, invasion, migration, and tumor growth in vivo. Furthermore, tRF-17-9L5FZU3 was shown to directly bind the 3'UTR of RhoB (Ras Homolog Family Member B) mRNA via dual-luciferase reporter assays, RNA pull-down, and AGO2 co-immunoprecipitation, leading to repression of RhoB expression at both mRNA and protein levels. RhoB was consistently downregulated in ESCC tumors and exhibited a significant inverse correlation with tRF-17-9L5FZU3 expression. Rescue experiments confirmed that oncogenic effects of tRF-17-9L5FZU3 were dependent on RhoB suppression. Moreover, tRF-17-9L5FZU3-knockdown decreased TGF-β secretion, increased IL-2 production, and inhibited PI3K/AKT and NF-κB signaling, which were reversed by co-silencing of RhoB. Collectively, these findings found that tRF-17-9L5FZU3 promoted ESCC malignancy by directly repressing RhoB, thereby activating oncogenic signaling pathways, positioning the tRF-17-9L5FZU3-RhoB axis as a critical regulator and potential therapeutic target in ESCC.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: